Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of SP-01 (Granisetron Patch) in Healthy Chinese Subjects
NCT05075876Phase 1Completed
- Sponsor
- Solasia Pharma
- Start
- Oct 2021
- Primary completion
- Dec 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of granisetron in chemotherapy-induced nausea and vomiting (CINV) (2 arms), sponsored by Solasia Pharma. Primary endpoints: Maximum observed drug concentration at 11 days, Area under the concentration-time curve 0-t at 11 days and 1 more. Started Oct 2021; status: completed.
02
Drugs
granisetron
03
Conditions
chemotherapy-induced nausea and vomiting (CINV)
Beyond the preview
Go deeper on NCT05075876.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05075876.